Navigation Links
Vitamin E trials 'fatally flawed'
Date:9/23/2007

CORVALLIS, Ore. Generations of studies on vitamin E may be largely meaningless, scientists say, because new research has demonstrated that the levels of this micronutrient necessary to reduce oxidative stress are far higher than those that have been commonly used in clinical trials.

In a new study and commentary in Free Radical Biology and Medicine, researchers concluded that the levels of vitamin E necessary to reduce oxidative stress as measured by accepted biomarkers of lipid peroxidation are about 1,600 to 3,200 I.U. daily, or four to eight times higher than those used in almost all past clinical trials.

This could help explain the inconsistent results of many vitamin E trials for its value in preventing or treating cardiovascular disease, said Balz Frei, professor and director of the Linus Pauling Institute at Oregon State University, and co-author of the new commentary along with Jeffrey Blumberg, at the Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University.

The methodology used in almost all past clinical trials of vitamin E has been fatally flawed, said Frei, one of the worlds leading experts on antioxidants and disease. These trials supposedly addressed the hypothesis that reducing oxidative stress could reduce cardiovascular disease. But oxidative stress was never measured in these trials, and therefore we dont know whether it was actually reduced or not. The hypothesis was never really tested.

The level of vitamin E that clearly can be shown to reduce oxidative stress, new research is showing, is far higher than the level that could be obtained in any diet, and is also above the tolerable upper intake level outlined by the Institute of Medicine, which is 1,000 I.U. a day. OSU researchers are not yet recommending that people should routinely take such high levels, but they do say that controlled clinical trials studying this issue should be aware of the latest findings and seriously consider using much higher vitamin E supplement levels in their studies.

In lab, animal or human studies, theres evidence that vitamin E can reduce oxidative stress, inhibit formation of atherosclerotic lesions, slow aortic thickening, lower inflammation, and reduce platelet adhesion. Some human studies using lower levels of vitamin E supplements, such as 100 to 400 I.U. a day, have shown benefits in reducing cardiovascular disease risk, and others have not. An underlying assumption was that these levels were more than adequate to reduce oxidative stress, since they far exceeded the recommended dietary allowance or RDA for the vitamin, a level adequate to prevent deficiency disease.

Whats now clear is that the amount of vitamin E than can conclusively be shown to reduce oxidative stress is higher than we realized, Frei said. And almost none of the studies done with vitamin E actually measured the beginning level or reduction of oxidative stress.

Proper studies of vitamin E, researchers say, must be done carefully and take into account the newest findings about this micronutrient. Its now known that natural forms of the vitamin are far more readily absorbed than synthetic types. Its also been discovered that supplements taken without a fat-containing meal are largely useless, because in the absence of dietary fat vitamin E is not absorbed.

Some clinical trials may wish to study the long term effect of vitamins on healthy individuals. But if a clinical trial seeks to learn the value of reducing oxidative stress, they should select patients in advance for those who have high, measurable oxidative stress often people who are older or have a range of heart disease risk factors, such as obesity, poor diet, hypertension or other problems. Cognizance should also be taken of people with health issues that may further increase their vitamin needs, such as smokers.

A pill count simply isnt enough to determine the value of vitamin E, Frei said. We need to select people for trials properly, make sure they are taking the right form of the vitamin, at the right levels and at the right time, and then verify the metabolic results with laboratory testing.

Only when we do these studies right will we answer questions about the value of vitamin E in addressing cardiovascular disease, he said. So far weve been flying blind.

A parallel, Frei said, would be presuming to test the value of a statin drug, which lowers cholesterol, without ever measuring cholesterol levels in the test subjects, neither at the beginning nor at the end of the study. Such trials would be ridiculed in the science community.

So far, thats the way vitamin E has been studied.

The use and intake of vitamins, experts say, has traditionally been thought of in terms of overt deficiency for example, not enough vitamin C causes scurvy. Much less research has been done on the levels that can help create optimum health. The issue is of special importance with modern populations that have very different diets, activity levels and increased lifespan, and are dying from much different causes predominantly heart disease and cancer than people of past generations.


'/>"/>

Contact: Balz Frei
balz.frei@oregonstate.edu
541-737-5078
Oregon State University
Source:Eurekalert

Related biology news :

1. Does vitamin C help prevent or treat the common cold? Maybe not, after all.
2. Vitamin As paradoxical role in influencing symmetry during embryonic development revealed
3. OHSU research shows vitamin C counteracts some negative impacts of smoking on unborn babies
4. Vitamin D deficiency widespread during pregnancy
5. Natural vitamin E tocotrienol reaches blood at protective levels
6. Poor athletic performance linked to vitamin deficiency
7. MIT biologists solve vitamin puzzle
8. Cocoa vitamin health benefits could outshine penicillin
9. Misusing vitamin to foil drug test may be toxic; plus, it doesnt work
10. Vitamins: Science doesnt always match policy
11. Fat overrides effects of vitamin C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... , Feb. 27, 2017   Strategic Cyber Ventures ... it has led a $3.5 million investment in  Polarity ... Strategic Cyber Ventures is DC based and is led ... Hank Thomas . Ron Gula , also a ... also participated in this series A round of funding. ...
(Date:2/24/2017)... , Feb. 24, 2017  EyeLock LLC, a leader ... its elite iris biometric solution on the latest ... LTE at Mobile World Congress 2017 (February ... Booth in Hall 3, Stand 3E10. ... Qualcomm Haven™ security platform—a combination of hardware, ...
(Date:2/21/2017)... and PORTLAND, Ore. , ... and the Avamere Family of Companies (Avamere Health Services, ... announced a six-month research study that will apply the ... eldercare at senior living and health centers. By analyzing ... hopes to gain insights into physical and environmental conditions, ...
Breaking Biology News(10 mins):
(Date:3/22/2017)... 2017 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), today announced ... U.K. Biobank and GSK to generate genetic sequence data from ... initiative will enable researchers to gain valuable insights to support ... range of serious and life threatening diseases. ... Genetic evidence has ...
(Date:3/22/2017)... 2017 Good Start Genetics, a leading family ... 130 million covered lives mark through its most recent ... Texas . With newly signed contracts nationally and ... strong payor acceptance based on the quality of its ... counseling, its industry-leading customer care and support and its ...
(Date:3/22/2017)... Florida , March 22, 2017 ... ... various cancer conditions are being pressured as of late due ... for cancer pain management has a dramatic impact on patient,s ... research and development activities for identifying new forms of opioid ...
(Date:3/22/2017)... ... ... Premier executive recruitment firm, Slone Partners, is proud to have been named a Top ... Hunt Scanlon Media is one of the most respected life science publications in the ... sector. , “It is a great honor for Slone Partners to be part of ...
Breaking Biology Technology: